Nebivolol
|
|
|
- CAS-Nr.
- 118457-14-0
- Englisch Name:
- Nebivolol
- Synonyma:
- R065824;Nobiten;Vasoxen;Nabilol;R-065824;R 065824;NEBIVOLOL;Nebivolol;dl-Nebivolol;L-Nebivolo1 D4
- CBNumber:
- CB92131013
- Summenformel:
- C22H25F2NO4
- Molgewicht:
- 405.43
- MOL-Datei:
- 118457-14-0.mol
|
Nebivolol Eigenschaften
- Schmelzpunkt:
- 155-156°C
- Siedepunkt:
- 600.5±55.0 °C(Predicted)
- Dichte
- 1.309
- storage temp.
- -20°C Freezer
- L?slichkeit
- DMSO (Slightly), Methanol (Slightly, Heated)
- pka
- pKa 8.22(H2O,t =25±1,Iundefined,Ar) (Uncertain)
- Aggregatzustand
- Solid
- Farbe
- White to Off-White
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung
|
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
|
P264, P270, P301+P312, P330, P501 |
|
| Sicherheit |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P270 |
Bei Gebrauch nicht essen, trinken oder rauchen. |
| P301+P312 |
BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen. |
| P330 |
Mund ausspülen. |
| P501 |
Inhalt/Beh?lter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
Nebivolol Chemische Eigenschaften,Einsatz,Produktion Methoden
History
The development of nebivolol began in the early 1980s, led by a research team at Janssen Pharmaceutica in Belgium. The design goal was to develop a novel cardiovascular drug with high β1-adrenergic receptor selectivity. The compound was successfully synthesized in the early 1990s, and its unique pharmacological characteristics lie in its dual mechanism of action: it is not only a highly potent third-generation β-blocker, but also promotes nitric oxide (NO)-mediated vasodilation by activating endothelial nitric oxide synthase (eNOS). This innovative mechanism of action was elucidated in the work of early researchers such as P. M. Vanhoutte. After systematic preclinical and clinical development, nebivolol received its first regulatory approval in Germany in 1997 for the treatment of essential hypertension. Subsequent extensive studies further established its clinical advantages in improving endothelial function and exhibiting better tolerability, distinguishing it from traditional β-blockers as a modern antihypertensive drug with vasodilatory properties.
Verwenden
Antihypertensive (β-blocker).
Nebivolol Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Nebivolol Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 69)Lieferanten
- NEBIVOLOL
- Unii-030Y90569u
- dl-Nebivolol
- [2R*[R*[R*(S*)]]]-alpha,alpha'-[Iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol
- (1S)-1-[(2R)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]-2-[[(2S)-2-[(2S)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]-2-hydroxyethyl]amino]ethanol
- NEBILET; BYSTOLIC; R 065824; R065824; R-065824
- R 065824
- R065824
- R-065824
- Nebivolol, racemic mixture
- 2H-1-Benzopyran-2-methanol, α,α'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-, (αR,α'R,2R,2'S)-rel-
- Nebivolol USP/EP/BP
- Nebivolol (R 065824)
- Nebivolol D4Q: What is
Nebivolol D4 Q: What is the CAS Number of
Nebivolol D4 Q: What is the storage condition of
Nebivolol D4 Q: What are the applications of
Nebivolol D4
- Nobiten
- Vasoxen
- Benzaldehyde,3-bromo-2-fluoro-9-(trifluoromethyl)-
- L-Nebivolo1 D4
- Nebivolol-d4-O-D-Glucuronide (Mixture of Diastereomers)
- Nabilol
- Nebivolol Impurity 111
- 2H-1-Benzopyran-2-methanol, a,a'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-, (aR,a'R,2R,2'S)-rel-
- Nebivolol
- D4-rac-Nebivolol.HCl
- (R)-1-((R)-6-fluorochroman-2-yl)-2-(((R)-2-((S)-6-fluorochroman-2-yl)-2-hydroxyethyl)amino)ethan-1-ol
- 118457-14-0
- Nebivolol
- Pharmaceuticals
